Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142

Transmission and spreading of tauopathy in transgenic mouse brain

Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803

Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526

Propagation of Tau Misfolding from the Outside to the Inside of a Cell

Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998

Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein

Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 763

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)

Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702

Glucocorticoids increase amyloid-β and tau pathology in a mouse model of alzheimer’s disease

Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., & LaFerla, F. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2797-06.2006 · Cited by 623

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Matsuo, E. S., Shin, R., Billingsley, M., de Voorde, A. V., O'Connor, M., Trojanowski, J., & Lee, V. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 588

Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease

Anand, K., & Sabbagh, M. N. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1075002 · Cited by 41

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Selenica, M.-L. B., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0152-0 · Cited by 40

Invited review: Drug development for tauopathies

Grüninger, F. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12192 · Cited by 40

Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia

Ji, M., Xie, X.-X., Liu, D., Yu, X., Zhang, Y., Zhang, L. L., Wang, S., Huang, Y., & Liu, R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0378-7 · Cited by 38

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease

Lambracht‐Washington, D., & Rosenberg, R. N. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31428 · Cited by 39

Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies

Kaufman, S. K., & Diamond, M. I. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0196-3 · Cited by 40

Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice Studies

Dupré, E., Danis, C., Arrial, A., Hanoulle, X., Homa, M., Cantrelle, F., Merzougui, H., Colin, M., Rain, J., Buée, L., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00217 · Cited by 37

Immunotherapy in Alzheimer’s Disease: Do We Have All the Pieces of the Puzzle?

Sarazin, M., Dorothée, G., de Souza, L. C., & Aucouturier, P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.011 · Cited by 37

Tau and Alzheimer's disease: Past, present and future

Iqbal, K. (2024) · Cytoskeleton · doi:10.1002/cm.21822 · Cited by 35

Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach

Shamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 34

New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease

Sergeant, N., Vingtdeux, V., Eddarkaoui, S., Gay, M., Evrard, C., Fur, N. L., Laurent, C., Caillierez, R., Obriot, H., Larchanché, P.-E., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.028 · Cited by 36

Alzheimer’s disease: phenotypic approaches using disease models and the targeting of tau protein

Lauretti, E., & Praticò, D. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1737012 · Cited by 34

Tau immunization: a cautionary tale?

Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 32

The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor

Kiefer, S. E., Chang, C., Kimura, S., Gao, M., Xie, D., Zhang, Y., Zhang, G., Gill, M. B., Mastalerz, H. A., Thompson, L. A., et al. (2014) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x14000144 · Cited by 31

MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice

Davtyan, H., Chen, W. W., Zagorski, K., Davis, J., Petrushina, I., Kazarian, K., Cribbs, D. H., Agadjanyan, M. G., Blurton-Jones, M., & Ghochikyan, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.020 · Cited by 30

Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine

Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 32

Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology

Joly‐Amado, A., Davtyan, H., Serraneau, K. S., Jules, P., Zitnyar, A., Pressman, E., Zagorski, K., Antonyan, T., Hovakimyan, A., Paek, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104636 · Cited by 30

Distinct dual roles of p-Tyr42 RhoA GTPase in tau phosphorylation and ATP citrate lyase activation upon different Aβ concentrations

Cap, K. C., Jung, Y., Choi, B. Y., Hyeon, S. J., Kim, J.-G., Min, J., Islam, R., Hossain, A. J., Chung, W., Suh, S. W., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101446 · Cited by 28

Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model

Leboucher, A., Ahmed, T., Caron, É., Tailleux, A., Raison, S., Joly‐Amado, A., Marciniak, E., Carvalho, K., Hamdane, M., Bantubungi, K., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.008 · Cited by 29

Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System

Perbet, R., Zufferey, V., Leroux, É., Parietti, E., Espourteille, J., Culebras, L., Perriot, S., Pasquier, R. D., Bégard, S., Deramecourt, V., et al. (2023) · Cells · doi:10.3390/cells12070985 · Cited by 31

Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites

Dillon, G. M., Henderson, J. L., Bao, C., Joyce, J. A., Calhoun, M. E., Amaral, B., King, K. W., Bajrami, B., & Rabah, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228771 · Cited by 26

Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy

Bajracharya, R., Cruz, E., Götz, J., & Nisbet, R. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.026 · Cited by 27

Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68–71) improves spatial memory in okadaic acid induced tauopathy model rats

Subramanian, S., Savanur, G., & Madhavadas, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.101 · Cited by 25

A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice

Hovakimyan, A., Antonyan, T., Shabestari, S. K., Svystun, O., Chailyan, G., Coburn, M., Carlen-Jones, W., Petrushina, I., Chadarevian, J. P., Zagorski, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51809-2 · Cited by 27

Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects

Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 28

Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders

Sidoryk‐Wȩgrzynowicz, M., Adamiak, K., & Strużyńska, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212448 · Cited by 26

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development

Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 25

Tau Immunotherapy and Imaging

Sigurdsson, E. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354491 · Cited by 23

Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

van Ameijde, J., Crespo, R., Janson, R., Juraszek, J., Siregar, B., Verveen, H., Sprengers, I., Nahar, T., Hoozemans, J. J. M., Steinbacher, S., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0562-9 · Cited by 21

Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy

Popelová, A., Pražienková, V., Neprašová, B., Kasperová, B. J., Hrubá, L., Holubová, M., Zemenová, J., Blum, D. L., Železná, B., Galas, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171041 · Cited by 22

Harnessing the Immune System for Treatment and Detection of Tau Pathology

Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20

SAR110894, a potent histamine H3‐receptor antagonist, displays disease‐modifying activity in a transgenic mouse model of tauopathy

Delay‐Goyet, P., Blanchard, V., Schussler, N., Lopez‐Grancha, M., Ménager, J., Mary, V., Sultan, E., Buzy, A., Guillemot, J.-C., Stemmelin, J., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.10.002 · Cited by 20

Tauopathies: Mechanisms and Therapeutic Strategies

Tan, C., Zhang, X.-Y., Tan, L., & Yu, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170187 · Cited by 21

Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy

Zimova, I., Brezováková, V., Hromádka, T., Weisová, P., Cubinkova, V., Valachova, B., Filipčík, P., Jadhav, S., Smolek, T., Novák, M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160347 · Cited by 19

Dementia Therapy Targeting Tau

Buée, L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_30 · Cited by 18

Clearing the way for tau immunotherapy in Alzheimer's disease

Herrmann, A. G., & Spires‐Jones, T. L. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12845 · Cited by 18

Engineered hepatitis B core virus-like particle carrier for precise and personalized Alzheimer’s disease vaccine preparation via fixed-point coupling

Ji, M., Xie, X.-X., Liu, D., Lü, S., Zhang, L. L., Huang, Y., & Liu, R. (2020) · Applied Materials Today · doi:10.1016/j.apmt.2020.100575 · Cited by 17

Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation

Richter, M., Mewes, A., Fritsch, M., Krügel, U., Hoffmann, R., & Singer, D. L. (2014) · Vaccines · doi:10.3390/vaccines2030601 · Cited by 17

Neurodegeneration Enhances the Development of Arthritis

Lang, S. C., Harre, U., Purohit, P., Dietel, K., Kienhöfer, D., Hahn, J., Baum, W., i, M. H., Schett, G. A., & Mielenz, D. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601472 · Cited by 16

Alzheimer's disease and immunotherapy.

Madeo, J., & Frieri, M. (2013) · Europe PMC (PubMed Central) · Cited by 15

Emerging amyloid and tau targeting treatments for Alzheimer’s disease

Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 16

Fungal Metabolites as Promising New Drug Leads for the Treatment of Alzheimer's Disease

Takahashi, J. A., Sande, D., Lima, G. D. S., Moura, M. A. F. E., & Lima, M. T. N. S. (2019) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64185-4.00001-0 · Cited by 14

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 16

Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice

Takamatsu-Yukawa, K., Yamamoto-Mcguire, S., Cafaro, L., Hong, C., Kamme, F., Ikezu, T., & Ikezu, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01661-3 · Cited by 12

Role of Tau protein in long COVID and potential therapeutic targets

Marwaha, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1280600 · Cited by 11

Effects of Tau Domain-Specific Antibodies and Intravenous Immunoglobulin on Tau Aggregation and Aggregate Degradation

Esteves-Villanueva, J. O., Trzeciakiewicz, H., Loeffler, D. A., & Martić, S. (2014) · Biochemistry · doi:10.1021/bi501272x · Cited by 12

Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein

Chukwu, J. E., Congdon, E. E., Sigurdsson, E. M., & Kong, X. (2019) · mAbs · doi:10.1080/19420862.2019.1574530 · Cited by 12

Sleep-wake variation in body temperature regulates tau secretion and correlates with CSF and plasma tau

Canet, G., Monteiro, F. D. G., Rocaboy, E., Diego-Diàz, S., Khelaifia, B., Godbout, K., Lachhab, A., Kim, J., Valencia, D. I., Yin, A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182931 · Cited by 11

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease

Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 11

New routes in frontotemporal dementia drug discovery

Conti, L. D., Borroni, B., & Baralle, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1329294 · Cited by 10

Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models

Alipour, M., Tebianian, M., Tofigh, N., Taheri, R. S., Mousavi, S. A., Naseri, A., Ahmadi, A., Munawar, N., & Shahpasand, K. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102285 · Cited by 9

Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers

Tan, W., Thiruppathi, J., Hong, S. H., Puth, S., Pheng, S., Mun, B.-R., Choi, W., Lee, K., Park, H., Nguyen, D. T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00904-1 · Cited by 10

Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer’s Disease

Strużyńska, L., Adamiak, K., & Sidoryk‐Wȩgrzynowicz, M. (2026) · Biomolecules · doi:10.3390/biom16040595 · Cited by 9

A novel Y-maze paradigm with enhanced sensitivity to subtle spatial recognition memory impairments in mice

Hadžibegović, S., Bontempi, B., & Nicole, O. (2025) · BMC Methods · doi:10.1186/s44330-025-00043-6 · Cited by 9

Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches

Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 9

Microtube Array Membrane Encapsulated Cell Therapy: A Novel Platform Technology Solution for Treatment of Alzheimer’s Disease

Chen, S., Hsu, T.-C., Chew, C. H., Huang, W., Chen, A. L., Lin, Y., Eddarkaoui, S., Buée, L., & Chen, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126855 · Cited by 7

The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy

Abdul‐Rahman, T., Herrera‐Calderón, R. E., Ahluwalia, A., Awuah, W. A., Ferreira, T., Tan, J. K., Wolfson, M., Ghosh, S., Horbas, V. A., Garg, V., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14678 · Cited by 9

Dale Schenk One Year Anniversary: Fighting to Preserve the Memories

Overk, C., & Masliah, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171071 · Cited by 5

Pathological conditions associated with tau protein: mechanisms of development and possible biological targets for pharmacological correction of tau proteinopathy (review)

Kuzubova, E. V., Radchenko, A. I., Pokrovsky, V. M., Patrakhanov, E. A., Novikova, A. A., Stepenko, Y. V., & Deykin, A. V. (2022) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2022-8-4-0-6 · Cited by 4

Tau Immunotherapy

Sigurdsson, E. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_8 · Cited by 3

Immunotherapeutics for AD: A Work in Progress

Sharma, A., Anand, J. S., & Kumar, Y. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210903101522 · Cited by 3

Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies

Méduri, G., Guillemeau, K., Daguinot, C., Dounane, O., Genet, M., Ferrara, L., Chambraud, B., Baulieu, E. E., & Giustiniani, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230127 · Cited by 3

Immunotherapies: A Treasure Trove of Alzheimer's Disease

Kolay, A., Neelam, N., Gupta, P., Shaikh, A. M., Goel, R., Nagpal, D., & Chitme, H. R. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010308600240709052539 · Cited by 2

Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome

Saternos, H., Hamlett, E. D., Guzman, S. J., Head, E., Granholm, A., & Ledreux, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240043 · Cited by 2

Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer’s Disease

Kazim, S. F., & Iqbal, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00002-8 · Cited by 2

Frontotemporal lobar degeneration

Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 3

Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy

Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2

Accumulation of Tau in Extracellular Vesicles Disturbs the Astrocytic Mitochondrial SystemPreprint

Perbet, R., Zufferey, V., Leroux, É., Parietti, E., Espourteille, J., Culebras, L., Perriot, S., du Pasquier, R., Bégard, S., Deramecourt, V., et al. (2023) · bioRxiv · doi:10.1101/2023.02.15.527595

Effect of MAPT gene variations on the brain electrical activity: A multiplex network study

Maturana-Candelas, A., Hornero, R., Poza, J., Rodríguez-González, V., Pablo, V. G.-D., Pinto, N., Rebelo, M. Â., & Gómez, C. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.108129 · Cited by 1

Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates

Wu, J., & Breydo, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00008-0 · Cited by 1

Prévenir la progression de la pathologie Tau par immunothérapie passive

Ozmen, L., & Collin, L. (2015) · médecine/sciences · doi:10.1051/medsci/20153102006 · Cited by 2

Vaccines Against Non-Infectious, Non-Cancer Novel Targets

Garside, D. A., Acevedo, R., Alsaadi, M., Nimmo, N., Gebril, A., Lamprou, D. A., Mullen, A. B., & Ferro, V. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00010-9 · Cited by 1

Investigación y terapias en la enfermedad de Alzheimer basadas en beta amiloide y tau

López-Camacho, P. Y., Guzmán-Hernández, R. N.-H., Gonzalez, V. H. H., Muñoz, J. E. D., García‐Sierra, F., & Basurto‐Islas, G. (2017) · Archivos de Neurociencias · doi:10.31157/an.v22i2.154 · Cited by 1

Role of Immunotherapy in Ameliorating Proteopathic Dementia

Singh, M., Pancham, P., Agarwal, S., Kaur, H., Agarwal, V., Tiwari, R. K., Mani, S., & Rachana, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7606-2_16 · Cited by 1

Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms

Yanamandra, K., Diamond, M. I., & Holtzman, D. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_9

Immunotherapy for the Treatment of Alzheimer’s Disease

Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00009-4

Proteinopathy: Shared Feature Between the Heart and Brain in Alzheimer's Disease

Amin, G., Booz, G. W., & Zouein, F. A. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001501 · Cited by 1

Sex-dependent effects of maternal high-fat diet during lactation in the offspring of adult THY-Tau22 mice

Gauvrit, T., Benderradji, H., Pelletier, A., Carvalho, K., Aboulouard, S., Faivre, É., Chatelain, E., Cannafarina, H., Labous, L., Launay, A., et al. (2025) · Brain · doi:10.1093/brain/awaf417

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Brown, C. M., Brooks, J. K., Kelly, L., Vroom, M. M., Longo, M., Dodart, J., Carare, R. O., & Boyd, J. D. (2025) · Brain Pathology · doi:10.1111/bpa.70056

Additional file 1 of Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice

Takamatsu-Yukawa, K., Yamamoto-Mcguire, S., Cafaro, L., Hong, C., Kamme, F., Ikezu, T., & Ikezu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26628664

Additional file 2 of Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice

Takamatsu-Yukawa, K., Yamamoto-Mcguire, S., Cafaro, L., Hong, C., Kamme, F., Ikezu, T., & Ikezu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26628667

Mouse models of Alzheimer’s disease pathology

Kim, S., & Gray, N. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29090-9.00004-0

Validation préclinique de l'efficacité de l'ANAVEX2-73 dans des modèles transgénique et non transgénique de la maladie d'Alzheimer

Lahmy, V. (2014) · theses.fr (ABES) · doi:10.70675/23744d67zb26bz4a32zadbfz3931ecca70f5

Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer

Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629

Implications de la protéine DYRK1A dans la pathologie Alzheimer et développement de stratégies thérapeutiques

Souchet, B. (2018) · theses.fr (ABES) · doi:10.70675/5510ef76zecf1z41f2z9496z015aa6a093be

Rôle de la dérégulation neuronale de la protéine kinase activée par l’AMP (AMPK) dans la pathologie tau, l’intégrité des synapses et le métabolisme énergétique : relevance pour la maladie d’Alzheimer

Domise, M. (2018) · theses.fr (ABES) · doi:10.70675/43c1f12fze623z41e8z970fz64a5de94a299

Study of the Neuron-Astrocyte Relationship in a Rodent Model of Tauopathy

de Gérando, A. M. (2019) · theses.fr (ABES) · doi:10.70675/04658671zaca3z4fefza24dz2f5a011bebfe

Caractérisation d'anticorps à domaine unique dirigés contre la protéine Tau

Danis, C. (2018) · theses.fr (ABES) · doi:10.70675/c783a062zb57bz4024z85d0z509baaed8a1b

Altered neuronal activity in the hippocampal CA3 region in an in vitro model of tauopathy

Goncalves, A. (2020) · theses.fr (ABES) · doi:10.70675/b42db6dez88a0z4a14z93eez8f51d19d46f5

Rôle des cellules T CD4+ dans la modulation des réponses microgliales au cours de la maladie d’Alzheimer : potentialités thérapeutiques

Ahmed, D. A. (2014) · theses.fr (ABES) · doi:10.70675/9f4f1101zd66fz4e13zadffzc6a36a19d81c

Hétérogénéité et régulation des astrocytes dans la maladie d'Alzheimer : vers des interventions ciblées sur les voies JAK2-STAT3 et NF-kB

Poulot-Becq-Giraudon, Y. (2024) · theses.fr (ABES) · doi:10.70675/0d7a8b92z8393z4d76z82a8z87efe0790346

Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies

Matta, K. (2024) · theses.fr (ABES) · doi:10.70675/cea4fe5ez67c3z4445z92f7z39af62ba059b

The Role of Tubulin Polyglutamylation in Controlling the Binding and Activity of Microtubule-Interacting Proteins

Genova, M. (2023) · theses.fr (ABES) · doi:10.70675/8bd8ddfeza950z4855z9c43zce2ac854ecf3

Understanding Alzheimer’s disease through biomarkers: pathology, progression, and clinical application

Zhang, X. T., Murphy, M., Riordan, H., Wang, K., Esquivel, R., Xu, W., Zhang, X., Gong, X., Sun, Y., & Lu, Y. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2740372

BindingDB Entry 50042999: Progress and developments in tau aggregation inhibitors for Alzheimer disease.

BindingDB (2014) · UC San Diego · doi:10.7270/q2ht2qqd

BindingDB Entry 50007132: Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.

BindingDB (2021) · UC San Diego · doi:10.7270/q2v98cc0

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.: Active Tau immunotherapy

Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F., Grosjean, M.-E., Zommer, N., Sergeant, N., Schraen‐Maschke, S., Blum, D., & Buée, L. (2012) · HAL

P2‐533: Targeting phospho‐Ser422 by active Tau immunotherapy in THY‐Tau22, a suitable therapeutic approach

Troquier, L., Caillierez, R., Burnouf, S., Kervoaze, G., Grosjean, M. E., Zommer, N., Sergeant, N., Lassalle, P., Blum, D. L., & Buée, L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1402 · Cited by 4

Immunotherapy approach in a mouse model of tau pathology

Troquier, L. (2011) · theses.fr (ABES)

P2‐527: Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves cognition in a mouse model

Boutajangout, A., Sait, H. B. R., González‐Calle, V., & Sigurdsson, E. M. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1396 · Cited by 3

Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies

Sigurdsson, E. M. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87